$DXCM
DexCom, Inc.
Continuous glucose monitoring systems for diabetes management.
DXCM key facts as of November 14, 2026
- Latest AI research report
- DXCM Stock: Growth, Valuation and Key Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Bullish (as of November 14, 2026)
- Analyst consensus
- Strong Buy (4 Strong Buy, 22 Buy, 3 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $97.85 mean (range $86.00 to $115.00) (as of November 20, 2026)
- Sector
- Healthcare
Analysis from Nov 13, 2026
DXCM Stock: Growth, Valuation and Key Risks
DexCom’s recent earnings beat, expanding CGM adoption and 11.2% reported revenue growth support a constructive outlook, while competition and valuation remain important counterweights. Here’s what Friday’s price, analyst expectations and upcoming catalysts suggest for DXCM.
Previous Reports
DXCM FAQ
What is StockAlpha's latest view on DXCM?
StockAlpha's latest AI research report on DexCom, Inc. (DXCM), "DXCM Stock: Growth, Valuation and Key Risks", was published on November 14, 2026 and rates the overall sentiment as bullish. DexCom’s recent earnings beat, expanding CGM adoption and 11.2% reported revenue growth support a constructive outlook, while competition and valuation remain important counterweights. Here’s what Friday’s price, analyst expectations and upcoming catalysts suggest for DXCM.
When was the DXCM research last updated?
The most recent DXCM report was published on November 14, 2026.
What do analysts expect for DXCM?
As of November 1, 2026, the analyst consensus on DXCM is Strong Buy (4 Strong Buy, 22 Buy, 3 Hold, 0 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $97.85 mean (range $86.00 to $115.00).
Is this DXCM research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft DexCom into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on DexCom's peers: Today's sector-level news and moves around the stock